AOD-9604 and Dozens of Compounds Catalogued in Clinical Trials Gateway
Background
Clinical drug development involves hundreds of compounds moving simultaneously through trials across diverse therapeutic areas. Tracking this landscape is difficult for researchers and clinicians without a consolidated reference. Prous Science Integrity's Clinical Studies Knowledge Area serves as a structured portal aggregating trial data across compounds. This digest format — covering agents from oncology and metabolic disease to anti-infectives and CNS disorders — provides a periodic snapshot of the active clinical pipeline. AOD-9604, a fragment analogue of human growth hormone, is among the peptide-based compounds tracked within this issue's selection, underscoring its presence in the formal clinical research ecosystem at the time of publication.
Study Design
No experimental study design is described in this publication. The data represents a registry-style compilation retrieved from the Prous Science Integrity portal (http://integrity.prous.com). Compounds were selected editorially for inclusion in this issue's tables. No animal models, cell lines, patient cohorts, dosing regimens, primary endpoints, or control arms are specified. The publication functions as a bibliographic and trial-status reference tool, not a primary research report.
Results
No quantitative experimental results are reported. The publication lists AOD-9604 alongside more than 100 other investigational compounds spanning a broad range of drug classes, including peptides, small molecules, monoclonal antibodies, and recombinant proteins. Other peptide-related entries in the same issue include exenatide, pramlintide acetate, recombinant glucagon-like peptide-1 (7-36) amide, recombinant human parathyroid hormone (1-84), hexyl insulin M2, human insulin, and metreleptin, illustrating the breadth of the peptide therapeutic pipeline captured.
AOD-9604 is explicitly named as one of the tracked compounds in this clinical trials gateway issue, confirming its active clinical trial status at time of publication.
No efficacy data, safety signals, p-values, fold-changes, or clinical endpoints are provided within the abstract for any listed compound, including AOD-9604.
Key Findings
- AOD-9604 explicitly listed as a tracked compound in the clinical trials gateway issue.
- Over 100 investigational compounds catalogued across multiple therapeutic areas.
- Multiple peptide therapeutics co-listed, including exenatide, pramlintide acetate, and recombinant GLP-1 (7-36) amide.
- Data sourced from Prous Science Integrity Clinical Studies Knowledge Area portal.
Why It Matters
Inclusion in a formal clinical trials gateway signals that AOD-9604 had reached a stage of development warranting systematic tracking in the peer-reviewed clinical literature. For clinicians and researchers, this type of registry digest establishes a timestamped record of which compounds were under active investigation, providing historical context for later efficacy and safety data. For those following AOD-9604's development trajectory, its co-listing with established peptide therapeutics such as exenatide and pramlintide acetate indicates it was considered a credible clinical candidate at the time. No dosing, indication, or protocol guidance can be derived from this source, and readers should consult primary trial registries for actionable clinical data.
